Return to homepagePandemic Pact

ACT-COAG Assessing coagulation biomarkers to accelerate the discovery of effective therapies for COVID-19 [Funder: PHRI]

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Other Funders (Canada)

  • Principal Investigator

    Noel and Guillaume and John and Emilie and Richard and Salim Chan and Paré and Eikelboom and Belley-Côté and Whitlock and Yusuf

  • Research Location

    Canada

  • Lead Research Institution

    N/A

  • Research Priority Alignment

    N/A

  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    N/A

  • Study Type

    Clinical

  • Clinical Trial Details

    Unspecified

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Thrombotic complications are common in COVID-19 cases; the objective of ACT-COAG is to measure the effect of study treatments on coagulation biomarkers to identify the most promising therapies early and unravel mechanisms of thrombotic complications. ACT COAG is a substudy of PHRI's ACT COVID-19 research program. PHRI is working in collaboration with scientists Jeffrey Weitz and Paul Kim at the Thrombosis and Atherosclerosis Research Institute (TaARI) in Hamilton, Canada, on the ACT COAG substudy.